医学 >>> 肿瘤学 >>> 肿瘤免疫学 肿瘤病因学 肿瘤病理学 肿瘤诊断学 肿瘤治疗学 肿瘤预防学 实验肿瘤学 肿瘤学其他学科
搜索结果: 1-15 共查到肿瘤学 immunotherapy相关记录19条 . 查询时间(0.032 秒)
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival fo...
近日,中南大学湘雅医院肿瘤科周蓉蓉教授脑转移MDT团队在国际著名期刊Journal for ImmunoTherapy of Cancer(肿瘤免疫治疗期刊,IF=12.485)以论著形式在线发表了题为“Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negativ...
Immunotherapy — drug treatment that stimulates the immune system to attack tumors — works well against some types of cancer, but it has shown mixed success against lung cancer.
整合含有天然免疫刺激分子的纳米制剂、以及个性化新抗原筛选技术,使肿瘤疫苗在临床测试展现了令人瞩目的有效性。新一代的肿瘤疫苗与CAR技术﹑免疫检查点干预成为免疫治疗中重要的三大板块。然而,在很多病人中,T细胞无法通过肿瘤屏障进入瘤内,导致对多种免疫治疗的不敏感;因此促进T细胞进入肿瘤,逆转肿瘤微环境成为提高免疫治疗效果的重要步。
Stimulating the body’s immune system to attack tumors is a promising way to treat cancer. Scientists are working on two complementary strategies to achieve that: taking off the brakes that tumors put ...
近年来,CAR-T疗法治疗血液源性肿瘤效果显著,然而在针对实体瘤的临床研究中却遭遇重大挑战。目前CAR-T均为靶点激活杀伤,而肿瘤靶点通常也在正常组织低表达,进而产生“on-target, off-tumor”现象、诱生炎症因子风暴、中枢神经毒性等,给CAR-T治疗带来严重的安全隐患。肿瘤细胞的异质性进一步导致靶点激活杀伤有效性受到挑战。即目前的靶点激活杀伤的CAR-T技术在在治疗实体瘤中,安全性...
Sachin Bhagchandani, a graduate student in the Department of Chemical Engineering currently working at the Koch Institute for Integrative Cancer Research, has won the National Cancer Institute Predoct...
癌细胞中程序性死亡配体1(PD-L1)的异常上调抑制T细胞介导的细胞毒性,但驱动和维持PD-L1表达的分子机制仍不完全清楚。PD-L1在肿瘤细胞内高尔基体等细胞器的驻留可能是影响抗体药物疗效的因素之一,但既往对其理解并不充分,使免疫检查点阻断疗法面临挑战。
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.There ...
Institute for Advanced Study scholars and collaborators have created the first mathematical model to predict how a cancer patient will respond to immunotherapy, according to a study published in Natur...
We are pleased to announce the Cold Spring Harbor Asia conference on Tumor Immunology & Immunotherapy which will be held in Suzhou, China, located approximately 60 miles west of Shanghai. The conferen...
Metastatic melanoma has a poor prognosis and until recently systemic therapy was ineffective. Advances in the understanding of tumour biology and immune regulation have led to the development of tar...
Treatment of melanoma by immunotherapy remains a topic of much interest. Initial studies were based on stimulation of immune responses by immunisation with whole cells or lysates of whole cells. Some...
Cancer immunotherapy aims to exploit and maximise the body’s own immune system in order to target and destroy cancer cells. The immune system is a complex and effective integrated network of specia...
Immunotherapy of melanoma     melanoma  Immunotherapy       2015/3/11
Melanoma is a cruel disease. The most recent Australian figures indicate that over 8000 cases of melanoma were reported in 1997 and that approximately 900 people died of the disease that year+ . O...

中国研究生教育排行榜-

正在加载...

中国学术期刊排行榜-

正在加载...

世界大学科研机构排行榜-

正在加载...

中国大学排行榜-

正在加载...

人 物-

正在加载...

课 件-

正在加载...

视听资料-

正在加载...

研招资料 -

正在加载...

知识要闻-

正在加载...

国际动态-

正在加载...

会议中心-

正在加载...

学术指南-

正在加载...

学术站点-

正在加载...